The Official Medicare Set Aside Blog And Information Resource

HHS Grants to Fight Opioid Addiction: How Could the Grants Impact Your MSA?

CMS, Medicare Set-Aside Blog, Opioids, Rx/Pharmacy on May 4, 2017 | Posted by Jean S. Goldstein, JD

Nationwide, states and workers’ compensation boards have been taking measures to curb the overprescribing and misuse of opioids and the crisis that has ensued as a result.  Nonetheless, opioid addiction continues to be a growing concern.  In an effort to help states combat the opioid epidemic, the U.S. Department of Health and Human Services (HHS) […] Continue

FDA Advisory Committee Finds Opana ER Risks Outweigh Benefits

FDA, Medicare Set-Aside Blog, Rx/Pharmacy on March 21, 2017 | Posted by Erin O'Neill, PA-C, JD

On March 14, 2017, a Food and Drug Administration (FDA) advisory committee found that the risks associated with use of Opana ER (oxymorphone hydrochloride) outweighed the potential benefits. Opana ER is an opioid pain medication, which was first introduced in 2006 and then reintroduced in a new abuse deterrent formulation in 2012. The new formulation was designed […] Continue

Arymo ER – Latest Addition to the Abuse Deterrent Opioids Market

FDA, Medicare Set-Aside Blog, Rx/Pharmacy on January 19, 2017 | Posted by Abidemi Oyebode, R.Ph., MBA - Clinical Pharmacist

Last week, the FDA approved Arymo ER, an abuse-deterrent formulation of morphine sulfate extended release tablets, marketed by Egalet Corporation. Arymo ER comes in three dosage strengths: 15mg, 30mg, and 60mg and slated to hit the market first quarter 2017.  Arymo ER is the latest addition to the growing list of abuse-deterrent opiates like Troxyca […] Continue

Ketamine Use in Workers’ Compensation: Yay or Nay?

Medicare Set-Aside Blog, Rx/Pharmacy on November 3, 2016 | Posted by Abidemi Oyebode, R.Ph., MBA - Clinical Pharmacist

Ketamine is a dissociative anesthetic approved by the FDA in 1970 to induce and maintain general anesthesia.  It is considered a dissociative drug because it distorts perceptions as well as produces feelings of detachment.  Ketamine is a potent open channel N-methyl-D-aspartate (NMDA)-receptor antagonist.  NMDA receptor excitation results in an influx of calcium into the cell […] Continue

The Latest Weapon in the Treatment of Opioid Addiction – Will Probuphine Live Up to the Hype?

Medicare Set-Aside Blog, Rx/Pharmacy on June 6, 2016 | Posted by Erin O'Neill, PA-C, JD

On May 26, 2016, the U.S. Food and Drug Administration (FDA) approved the first implant of its kind designed to provide maintenance treatment of opioid dependence. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm503719.htm Probuphine, developed by Braeburn Pharmaceuticals utilizing Titan Pharmaceuticals’ continuous drug delivery system, is a small implant that is made from a mixture of ethylene-vinyl acetate and 80mg of […] Continue

FDA Advisory Committees Weigh in on New Abuse-Deterrent Opioid Medications

Medicare Set-Aside Blog, Rx/Pharmacy on May 5, 2016 | Posted by Erin O'Neill, PA-C, JD

On the heels of the release of the FDA’s guidelines for the development of generic formulations for abuse-deterrent opioid medications, the FDA Advisory Committees have weighed in on several proposed abuse-deterrent opioid medications. On April 26, 2016, the U.S. Food and Drug Administration (FDA) approved a new long-acting opioid medication designed for the management of […] Continue

The Opioid Crisis: A Call to Action

Rx/Pharmacy on March 25, 2016 | Posted by Abidemi Oyebode, R.Ph., MBA - Clinical Pharmacist

The National Survey on Drug Use and Health (NSDUH) showed that in 2012 about 2.1 million Americans were addicted to opioid pain medications, roughly 467,000 addicted to heroin and about 2.5 million Americans with opioid use disorder but receiving legitimate prescriptions.  According to the CDC, opioids were involved in 16, 235 deaths in 2013 and […] Continue

FDA to Require Black Box Warning on All Immediate-Release Opioid Medications

Medicare Set-Aside Blog, MSP News, News and Events, Rx/Pharmacy on March 22, 2016 | Posted by Erin O'Neill, PA-C, JD

On Tuesday, March 22, 2016, the U.S. Food and Drug Administration (FDA) announced it will now require a black box warning on all immediate-release opioid medications. This warning will address issues regarding the risks of abuse, addiction, misuse, overdose and death. The FDA had indicated that immediate-release opioid medications should be reserved for individuals with […] Continue

Management of Opioid Induced Hyperalgesia – The Impact on Workers’ Compensation Claims

CMS, Medicare Set-Aside Blog, Medicare Set-Asides, Rx/Pharmacy, Work Comp on November 9, 2015 | Posted by Abidemi Oyebode, R.Ph., MBA - Clinical Pharmacist

The impact of opioid use in workers’ compensation claims has been widely researched and the shocking results continue to reveal that opioid use remains a very significant concern for workers’ compensation carriers. As evidenced by the NCCI Workers’ Compensation Prescription Drug Study: 2013 Update, the average narcotic cost per claim continued to increase as did […] Continue

Avinza Extended-Release Capsules No Longer Being Manufactured

Medicare, Medicare Set-Asides, Rx/Pharmacy on July 22, 2015 | Posted by Erin O'Neill, PA-C, JD

The Food and Drug Administration (FDA) has announced that all strengths of Avinza (morphine sulfate) extended release capsules have been discontinued. Avinza is a Schedule II long acting opioid medication indicated for the treatment of severe pain only. Avinza carried a black box warning indicating that misuse could lead to death due to the lack […] Continue